Health Canada finds bacteria in seized peptide vials: the November 2026 advisories
BPC-157 MOTS-c Retatrutide Tesamorelin
Health Canada found bacteria in seized injectable peptides in two November 2026 advisories, seized over 11,400 vials, and said research-only labels do not exempt products.
Health Canada issued two public advisories in November 2026 after its laboratory found bacteria in seized injectable peptide products. The first, on November 6, covered vials from a Shanghai manufacturer and two Canadian online retailers. The second, on November 12, covered a wellness store in Ottawa. Some seized vials were labelled for research purposes only, and the department said that label does not exempt them from Canadian drug rules.
Research material: BPC-157 at Fifth Ave Labs · BPC-157 at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Research material: MOTS-c at Fifth Ave Labs · MOTS-c at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Research material: FAL-3RT at Fifth Ave Labs · LP-3 RT at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Research material: FAL-Tesa at Fifth Ave Labs. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
What the November 6 advisory found
The first advisory (identification number RA-82930) concerns Shanghai ERP Peptide Biotechnology Co. Ltd., known as ERP Peptide. Health Canada says it seized and tested injectable peptides from the company. It found bacteria including Acinetobacter seifertii, Acinetobacter nosocomialis and Propionibacterium (Cutibacterium) acnes.
The department traced ERP Peptide products to two Canadian online retailers, truenorthbiolabs.ca and bcaxiompeptide.com. It obtained court-issued entry warrants and seized product from both. It says both websites are no longer active. In total, it seized more than 11,400 vials from ERP Peptide and the two retailers.
The advisory lists examples of unauthorized products sold by ERP Peptide: human chorionic gonadotropin (hCG), MOTS-c, NAD+, retatrutide, tesamorelin and tirzepatide. It does not say which of these products tested positive. Its title refers to "peptide and non-peptide drugs"; NAD+, for example, is a coenzyme rather than a peptide.
Health Canada also asked ERP Peptide to stop selling peptides into Canada. It is working with the Canada Border Services Agency to stop shipments at the border.
What the November 12 advisory found
Six days later, Health Canada warned about products seized from Sage & Summit Wellness Co. in Ottawa. The seizure followed a consumer complaint that the store sold unauthorized peptides in-store and online. Testing found Sphingomonas aquatilis/melonis in one injectable product.
Coverage of the advisory lists peptides marketed as BPC-157, TB-500, retatrutide, MOTS-c, tesamorelin, Semax and Melanotan-1. Benefits and Pensions Monitor reports that the advisory names ten injectable products and one oral BPC-157 capsule. The store agreed to stop selling through both channels.
Reuters reported that some seized vials carried a "For Research Purposes Only" label. Health Canada said that wording does not make a product legal or exempt it from regulatory requirements. It added that the products had not been made or tested to quality standards for human-use health products. Reuters described retatrutide as an Eli Lilly obesity drug candidate that is not yet approved.
How Canada classifies injectable peptides
Health Canada's peptide regulation page, updated October 23, 2026, says injectable peptides are always classified as drugs under the Food and Drug Regulations. It cites the higher risks of injection, which call for stricter controls on sterility, safety and quality. Injectable products cannot be natural health products in Canada.
Authorized peptide products carry an eight-digit Drug Identification Number (DIN) or Natural Product Number (NPN). Products without one have not been assessed by Health Canada. The page lists the enforcement tools the department uses against unauthorized peptides:
- recalls and product seizures
- requests to stop sales
- court-issued entry warrants
- permanent court injunctions to stop non-compliant activity
- ministerial orders to stop advertising and sale
The page says complaints about online sales of unauthorized peptides have increased. It also says the department is working with provincial and territorial regulators on peptides being compounded in Canada.
How this differs from the US position
The Canadian actions follow a different move in the United States. On October 28, 2026, HHS published an interim enforcement discretion policy for 503A pharmacy compounding with six peptides, including BPC-157, TB-500, MOTS-c and Semax. Our earlier post covers that policy. It is not an approval, and it does not cover research-use-only material.
The two systems now treat several of the same compounds very differently. A peptide that a US pharmacy may compound under set conditions remains an unauthorized drug in Canada if it has no DIN. For the US categories in more detail, see are peptides legal and the regulatory tracker.
Human evidence for several of the named compounds is limited. BPC-157 and TB-500 rest mainly on animal and cell studies, and MOTS-c has very little interventional human data.
What the findings mean for laboratory material
Neither advisory reports purity, identity or endotoxin results. They report bacteria found in specific seized products. Health Canada lists microbial contamination, including bacteria, fungi and endotoxins, among the quality risks of unauthorized products. It lists wrong amounts of active ingredient and unlisted ingredients alongside it.
An HPLC purity figure measures related peptide impurities, not microbial load. A certificate that reports only identity and purity says nothing about sterility or endotoxin. See endotoxin testing, sterile filtration and how to read a COA for what each test covers. The COA checker is another place to start when reviewing a certificate.
Research material: BPC-157 at Fifth Ave Labs · BPC-157 at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Research material: MOTS-c at Fifth Ave Labs · MOTS-c at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Research material: FAL-3RT at Fifth Ave Labs · LP-3 RT at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Research material: FAL-Tesa at Fifth Ave Labs. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.
Sources
- Health Canada: Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs, RA-82930 (2026-11-06)
- Health Canada: Peptides: Regulations and enforcement (2026-10-23)
- Reuters via Yahoo News: Health Canada warns after bacteria found in unauthorized peptides (2026-11-12)
- Benefits and Pensions Monitor: Health Canada seizes unauthorized peptide vials six days apart (2026-11-16)
- American Med Spa Association: Health Canada warns against unauthorized peptides after bacteria found in seized products (2026-11-19)
- CTV News: 'Do not buy or use': Health Canada finds dangerous bacteria in seized drugs from China (2026-11-09)
Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.
More from the blog
- What is a peptide bond? Resonance, cis/trans isomers and how it forms and breaks
- Cagrilintide: what the amylin analog's trials show and where FDA review stands
- AMA urges HHS to rescind its peptide compounding policy as the comment period closes
- Peptide purity: what the HPLC percentage on a COA measures and what it misses